FY2024 Earnings Forecast for NAMS Issued By HC Wainwright

NewAmsterdam Pharma (NASDAQ:NAMS) – Investment analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of NewAmsterdam Pharma in a note issued to investors on Monday, December 30th. HC Wainwright analyst E. Arce forecasts that the company will earn ($1.64) per share for the year. HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.78) EPS and FY2028 earnings at ($1.04) EPS.

Other equities research analysts have also issued research reports about the stock. Piper Sandler reiterated an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Buy” and a consensus price target of $38.17.

NewAmsterdam Pharma Price Performance

Shares of NAMS opened at $25.70 on Wednesday. The firm has a fifty day moving average price of $22.26 and a 200-day moving average price of $19.26. NewAmsterdam Pharma has a 12-month low of $11.18 and a 12-month high of $27.29.

Insider Buying and Selling

In other news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the sale, the insider now directly owns 11,778,760 shares in the company, valued at approximately $295,411,300.80. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 416,884 shares of company stock valued at $10,676,428 over the last 90 days. Corporate insiders own 19.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Banque Cantonale Vaudoise purchased a new stake in NewAmsterdam Pharma in the second quarter valued at about $38,000. Quarry LP increased its holdings in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after acquiring an additional 6,247 shares in the last quarter. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG purchased a new stake in NewAmsterdam Pharma during the 3rd quarter worth approximately $128,000. Finally, XTX Topco Ltd acquired a new position in NewAmsterdam Pharma during the 3rd quarter valued at approximately $187,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.